Is Shree Ganesh Rem overvalued or undervalued?

As of 10 October 2025, the valuation grade for Shree Ganesh Rem has moved from expensive to fair. The company is currently fairly valued based on its financial ratios, which include a PE Ratio of 29.32, an EV to EBITDA of 17.00, and a ROCE of 19.10%. In comparison to its peers, Sun Pharma has a higher PE Ratio of 34.96 and an EV to EBITDA of 23.7, indicating that Shree Ganesh Rem is more attractively priced within the industry.
When considering the broader market context, Shree Ganesh Rem's stock has underperformed relative to the Sensex, with a year-to-date return of -21.58% compared to the Sensex's 5.58%. This underperformance, combined with its current valuation metrics, suggests that the company is positioned fairly in the market, making it a potential candidate for investors looking for stability in the pharmaceuticals and biotechnology sector.